Skip to main content

Table 3 Gene expression analysis of DCK in a set of primary MCL samples obtained from patients before and after araC-based therapies

From: Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents

Sample at diagnosis

Source

∆CT (DCK-GAPDH)

Therapy

Sample at relapse

Disease-free survival (months)

Source

∆CT (DCK-GAPDH)

Difference in ∆CT between R and D samples

D1

PBMC

3.4

A*

R1

12

PBMC

3.7

+0.3

D2

PE***

3.3

A

R2

10

PE***

5.3

+2.0

D3

FFPE

0.1

A

R3

5

FFPE

1.3

+1.2

D4

FFPE

1.7

B

R4

4

FFPE

3.5

+1.8

D5

PBMC

1.4

A

R5

7

PBMC

2.2

+0.8

D6

PBMC

4.1

B**

R6

3

PBMC

3.9

−0.2

D7

FFPE

1.3

B

R7

13

FFPE

3.5

+2.2

D8

FFPE

2.0

A

R8

25

FFPE

1.8

−0.2

D9

PBMC

1.9

B

R9

N/A

PBMC

3.3

+1.4

D10

PBMC

2.3

A

R10

N/A

PBMC

1.5

−0.8

  1. *A = alternation of R-CHOP and R-araC (2 g/m2, 2 doses a 24 h).
  2. **B = Nordic protocol (alternation of R-MaxiCHOP and R-araC (2-3 g/m2, 4 doses a 12 h).
  3. ***PE pleural effusion (CD19-sorted).
  4. Samples from relapsed patients were obtained at diagnosis (D1-D8) and at lymphoma relapse after failure of araC-based therapies (R1-R8). Samples from refractory patients were obtained from primary araC-resistant MCL patients before (D9-D10) and 14 days after (R9-R10) administration of high-dose araC. Real-time RT-PCR was used to determine changes in DCK expression.